Under a tenth of people who could benefit from obesity jabs like Wegovy have access to them, warns the WHO as it issues its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be managed with thorough and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major hurdles to universal availability to the injections that can assist patients in reducing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Even under the current best projected outlook, the supply of such drugs could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The guideline urges nations and manufacturers to increase access, through approaches including patent sharing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in several nations in 2026.
The Way Obesity Jabs Operate
The injections mimick a body's own hormone to slow digestion, reduce hunger and enhance satiety so users eat less.
Patients typically see weight reduction within a few weeks of beginning the regular doses.
Studies indicates patients may put most of the weight back on a year later of stopping the drug, as their normal hunger return.
To be carrying excess weight elevates your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
